Synopsis Neuroendocrine Tumor (NET) of unknown primary is a rare disease. Despite this, the prevalence of NET is increasing considerably. The present study aims to evaluate the clinical activity and safety of capecitabine and temozolomide in NETs of unknown primary. This week’s “ MED FACT ” discusses a clinical trial from the Journal Of Oncology, “ Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary”. Authors : A. Chauhan et.
al. Key Takeaways: Treatment with capecitabine and temozolomide shows improvement in progression-free survival of grade I and grade II NETs of unknown primary. Objective: To evaluate the clinical activity and safety of Capecitabine and Temozolomide in NET of unknown primary. Study Type Retrospective study Participants: 12 What was the need for this study? Chemotherapeutic options are lacking for the rising prevalence NETs of unknown…
